Abstract
Long noncoding RNAs (lncRNAs) are a class of RNA with 200 nucleotides or longer that are not translated into protein. lncRNAs are highly abundant; a study estimates that at least four times more lncRNAs are typically present than coding RNAs in humans. However, function of more than 95% of human lncRNAs are still unknown. Synthetic antisense oligonucleotides called gapmers are powerful tools for lncRNA loss-of-function studies. Gapmers contain a central DNA part, which activates RNase H-mediated RNA degradation, flanked by modified oligonucleotides, such as 2′-O-methyl RNA (2′OMe), 2′-O-methoxyethyl RNA (2′MOE), constrained ethyl nucleosides (cEt), and locked nucleic acids (LNAs). In contrast to siRNA or RNAi-based methods, antisense oligonucleotide gapmer-based knockdown is often more effective against nuclear-localized lncRNA targets, since RNase H is mainly localized in nuclei. As such, gapmers are also potentially a powerful tool for therapeutics targeting lncRNAs in various diseases, including cancer, cardiovascular diseases, lung fibrosis, and neurological/neuromuscular diseases. This chapter will discuss the development and applications of gapmers for lncRNA loss-of-function studies and tips to design effective antisense oligonucleotides.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Costa FF (2010) Non-coding RNAs: meet thy masters. BioEssays 32(7):599–608
Beermann J, Piccoli M-T, Viereck J et al (2016) Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev 96(4):1297–1325
Gomes AQ, Nolasco S, Soares H (2013) Non-coding RNAs: multi-tasking molecules in the cell. Int J Mol Sci 14(8):16010–16039
Krishnan P, Ghosh S, Graham K et al (2016) Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer. Oncotarget 7(25):37944
Yin Q-F, Yang L, Zhang Y et al (2012) Long noncoding RNAs with snoRNA ends. Mol Cell 48(2):219–230
Ho PY, Yu AM (2016) Bioengineering of noncoding RNAs for research agents and therapeutics. Wiley Interdiscip Rev RNA 7(2):186–197
Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12(12):861
Engreitz JM, Ollikainen N, Guttman M (2016) Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol 17(12):756
Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155
Volders PJ, Anckaert J, Verheggen K et al (2019) LNCipedia 5: towards a reference set of human long non-coding RNAs. Nucleic Acids Res 47(D1):D135–D139. https://doi.org/10.1093/nar/gky1031
Moran VA, Perera RJ, Khalil AM (2012) Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res 40(14):6391–6400
Chen L-L (2016) Linking long noncoding RNA localization and function. Trends Biochem Sci 41(9):761–772
Cabili MN, Dunagin MC, McClanahan PD et al (2015) Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution. Genome Biol 16(1):20
van Heesch S, van Iterson M, Jacobi J et al (2014) Extensive localization of long noncoding RNAs to the cytosol and mono-and polyribosomal complexes. Genome Biol 15(1):R6
Lennox KA, Behlke MA (2016) Mini-review: current strategies to knockdown long non-coding RNAs. J Rare Dis Res Treat 1:66–70
Lennox KA, Behlke MA (2015) Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res 44(2):863–877
Szafranski P, Karolak JA, Lanza D et al (2017) CRISPR/Cas9-mediated deletion of lncRNA Gm26878 in the distant Foxf1 enhancer region. Mamm Genome 28(7–8):275–282
Yang J, Meng X, Pan J et al (2018) CRISPR/Cas9-mediated noncoding RNA editing in human cancers. RNA Biol 15(1):35–43
Aparicio-Prat E, Arnan C, Sala I et al (2015) DECKO: single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs. BMC Genomics 16(1):846
Gutschner T (2015) Silencing long noncoding RNAs with genome-editing tools. In: Chromosomal mutagenesis. Springer, New York, pp 241–250
Koirala P, Zou D-H, Mo Y-Y (2016) Long non-coding RNAs as key regulators of cancer metastasis. J Cancer Metastasis Treat 2:1–10
Salehi M, Sharifi M, Bagheri M (2019) Knockdown of long noncoding RNA plasmacytoma variant translocation 1 with antisense locked nucleic acid GapmeRs exerts tumor-suppressive functions in human acute erythroleukemia cells through downregulation of C-MYC expression. Cancer Biother Radiopharm 34(6):371–379
Inoue H, Hayase Y, Iwai S et al (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett 215(2):327–330. https://doi.org/10.1016/0014-5793(87)80171-0
GrÜnweiler A, Hartmann RK (2007) Locked nucleic acid oligonucleotides. BioDrugs 21(4):235–243
Gait MJ, Agrawal S (2019) Advances in nucleic acid therapeutics, vol 68. Royal Society of Chemistry, London
Nakamura H, Oda Y, Iwai S et al (1991) How does RNase H recognize a DNA. RNA hybrid? Proc Natl Acad Sci U S A 88(24):11535–11539
Seth PP, Jazayeri A, Yu J et al (2012) Structure activity relationships of α-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol Ther Nucleic Acids 1:e47
Lundin KE, Gissberg O, Smith CI (2015) Oligonucleotide therapies: the past and the present. Hum Gene Ther 26(8):475–485. https://doi.org/10.1089/hum.2015.070
Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144–176. https://doi.org/10.3390/jpm3030144
Matsui M, Corey DR (2017) Non-coding RNAs as drug targets. Nat Rev Drug Discov 16(3):167
Khan H, Missailidis S (2008) Antisense Agents. In: Anticancer therapeutics, vol 317. Wiley, Chichester
Shen W, De Hoyos CL, Migawa MT et al (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37(6):640–650
Naessens S, Ruysschaert L, Lefever S et al (2019) Antisense oligonucleotide-based downregulation of the G56R pathogenic variant causing NR2E3-associated autosomal dominant retinitis Pigmentosa. Genes 10(5):363
Yoshida T, Naito Y, Yasuhara H et al (2019) Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells. Genes Cells 24(12):827–835
Markham NR, Zuker M (2008) UNAFold: software for nucleic acid folding and hybridization. Methods Mol Biol 453:3–31. https://doi.org/10.1007/978-1-60327-429-6_1
Paz I, Kosti I, Ares M Jr et al (2014) RBPmap: a web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res 42:W361–W367. https://doi.org/10.1093/nar/gku406
Pedersen L, Hagedorn PH, Lindholm MW et al (2014) A kinetic model explains why shorter and less affine enzyme-recruiting oligonucleotides can be more potent. Mol Ther Nucleic Acids 3:e149. https://doi.org/10.1038/mtna.2013.72
Tolstrup N, Nielsen PS, Kolberg JG et al (2003) OligoDesign: optimal design of LNA (locked nucleic acid) oligonucleotide capture probes for gene expression profiling. Nucleic Acids Res 31(13):3758–3762
Moreno PM, Ferreira AR, Salvador D et al (2018) Hydrogel-assisted antisense LNA Gapmer delivery for in situ gene silencing in spinal cord injury. Mol Ther Nucleic Acids 11:393–406
Leti F, DiStefano J (2017) Long noncoding RNAs as diagnostic and therapeutic targets in type 2 diabetes and related complications. Genes 8(8):207
Chung S, Nakagawa H, Uemura M et al (2011) Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 102(1):245–252
Guan Y, Kuo W-L, Stilwell JL et al (2007) Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 13(19):5745–5755
Panzitt K, Tschernatsch MM, Guelly C et al (2007) Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132(1):330–342
Pibouin L, Villaudy J, Ferbus D et al (2002) Cloning of the mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon carcinomas. Cancer Genet Cytogenet 133(1):55–60
Bussire T, Gold G, Kvari E et al (2003) Stereologic analysis of neurofibrillary tangle formation in prefrontal cortex area 9 in aging and Alzheimer’s disease. Neuroscience 117(3):577–592
Lukiw W, Handley P, Wong L et al (1992) BC200 RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD). Neurochem Res 17(6):591–597
Nair M, Sagar V, Pilakka-Kanthikeel S (2016) Gene-expression reversal of lncRNAs and associated mRNAs expression in active vs latent HIV infection. Sci Rep 6:34862
Zhang Q, Chen C-Y, Yedavalli VS et al (2013) NEAT1 long noncoding RNA and paraspeckle bodies modulate HIV-1 posttranscriptional expression. MBio 4(1):e00596–e00512
Ishii N, Ozaki K, Sato H et al (2006) Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet 51(12):1087
Gutschner T, Hämmerle M, Diederichs S (2013) MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med 91(7):791–801
Liu J, Yao J, Li X et al (2014) Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 5(10):e1506
Arun G, Diermeier SD, Spector DL (2018) Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 24(3):257–277
Amodio N, Stamato MA, Juli G et al (2018) Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia 32(9):1948
Castillo AS, Mateos CO, Riera MS et al (2019) Non-coding RNAs as key players for understanding oncogenic pathways in ovarian cancer: studying new therapeutic strategies. AACR, Philadelphia
Woo CJ, Maier VK, Davey R et al (2017) Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proc Natl Acad Sci U S A 114(8):E1509–E1518
Goodkey K, Aslesh T, Maruyama R et al (2018) Nusinersen in the treatment of spinal muscular atrophy. In: Exon skipping and inclusion therapies. Springer, New York, pp 69–76
Viereck J, Kumarswamy R, Foinquinos A et al (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8(326):326ra322
Jiang D, Liang J (2019) A lncRNA Links TGF-β Signaling in Lung Fibrosis. Am J Respir Crit Care Med 200(2):123–125
Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213–4218. https://doi.org/10.1073/pnas.1613203114
Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198–203. https://doi.org/10.1073/pnas.0406700102
Ezzat K, Aoki Y, Koo T et al (2015) Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett 15(7):4364–4373. https://doi.org/10.1021/acs.nanolett.5b00490
Walker I, Irwin WJ, Akhtar S (1995) Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 12(10):1548–1553
Echigoya Y, Aoki Y, Miskew B et al (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https://doi.org/10.1038/mtna.2014.76
Acknowledgments
This work is supported by Muscular Dystrophy Canada, the Friends of Garrett Cumming Research Fund, HM Toupin Neurological Science Research Fund, Canadian Institutes of Health Research (CIHR), Alberta Innovates: Health Solutions (AIHS), Canada Foundation for Innovation (CFI), Alberta Advanced Education and Technology, and Women and Children’s Health Research Institute (WCHRI).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Maruyama, R., Yokota, T. (2020). Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers. In: Yokota, T., Maruyama, R. (eds) Gapmers. Methods in Molecular Biology, vol 2176. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0771-8_3
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0771-8_3
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0770-1
Online ISBN: 978-1-0716-0771-8
eBook Packages: Springer Protocols